Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis
Author:
Affiliation:
1. At time of research; Bristol-Myers Squibb; Princeton NJ USA
2. Orlando Clinical Research Center; Orlando FL USA
3. Pfizer Inc; Groton CT USA
Funder
Bristol-Myers Squibb Foundation
Pfizer
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.628/fullpdf
Reference22 articles.
1. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial;Lassen;Lancet,2010
2. Apixaban or enoxaparin for thromboprophylaxis after knee replacement;Lassen;N Engl J Med,2009
3. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement;Lassen;N Engl J Med,2010
4. Apixaban in patients with atrial fibrillation;Connolly;N Engl J Med,2011
5. Apixaban versus warfarin in patients with atrial fibrillation;Granger;N Engl J Med,2011
Cited by 240 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients;Kidney International Reports;2024-09
2. Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients;International Journal of Molecular Sciences;2024-08-09
3. Apixaban Use in Patients with Kidney Impairment: A Review of Pharmacokinetic, Interventional, and Observational Study Data;American Journal of Cardiovascular Drugs;2024-08-05
4. Warfarin-induced calciphylaxis-related skin ulceration in patients with end-stage renal disease: case report and literature review;Journal of Wound Care;2024-08-02
5. Reprint of: Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis;Journal of the American Pharmacists Association;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3